Clinical Trial Highlights from the American Heart Association Scientific Sessions 2013 (AHA13)

Over the next couple of weeks, I will be providing trial summaries and commentary on all of the medication-related late-breakers from the American Heart Association Scientific Sessions (AHA13). Although there were few breakthroughs presented at the meeting, Marc Pfeffer, MD, PhD, professor at the Harvard Medical School and lead investigator for the TOPCAT trial, cautioned attendees to refrain from calling the results negative, as the true purpose of research is to learn even if the results are not beneficial.

Keep checking back for updates!

Posted as of December 7, 2013:

• ENGAGE-AF: edoxaban vs. warfarin in patients with atrial fibrillation
• COAG, EU-PACT: pharmacogenomic-guided dosing strategies for warfarin
• TOPCAT: spironolactone vs. placebo in heart failure with preserved ejection fraction 
• ROSE AHF: low-dose dopamine of low-dose nesiritide in acute decompensated heart failure